FDA Approves PharmaEssentia's BESREMi as the First New Essential Thrombocythemia Treatment in Decades

The US Food and Drug Administration has approved PharmaEssentia's BESREMi, known generically as ropeginterferon alfa-2b, for adults with essential thrombocythemia, a rare blood cancer that causes the bone marrow to produce too many platelets and that carries a heightened risk of dangerous blood clots. Healio reported on Sep 1 that the decision marks the first new treatment approved for essential thrombocythemia in nearly three decades, and the first therapy designed for the disease regardless of a patient's genetic subtype or treatment history. The approval, which the company announced on August 31, extends BESREMi's reach beyond polycythemia vera, a related blood cancer for which the drug was already approved, and it hands the Taiwan-based biopharmaceutical company a second indication in a class of diseases that has seen little innovation for a generation.

Essential thrombocythemia, often abbreviated ET, is one of a family of chronic blood cancers known as myeloproliferative neoplasms, in which the bone marrow produces excess blood cells. In ET the overproduction is of platelets, the cell fragments that help blood clot, and patients face elevated risks of thrombosis, including heart attacks, strokes and pulmonary embolism, as well as bleeding when platelet function is abnormal. The disease has historically been managed with older cytoreductive drugs such as hydroxyurea and anagrelide, neither of which was designed to target the underlying malignant clone, and both of which come with tolerability limitations that leave many patients without an adequate option. The approval of BESREMi, a long-acting interferon formulated to be dosed every two weeks, gives those patients a mechanistically different choice for the first time in decades.

Key Facts

The clinical evidence behind the approval comes from the global Phase 3 SURPASS ET trial, which enrolled 174 adults with essential thrombocythemia who had an inadequate response to, or could not tolerate, hydroxyurea, according to Healio's Sep 1 report. Patients were randomized to receive either BESREMi or anagrelide plus aspirin, and the results showed a durable modified European Leukemia Net response rate at months 9 and 12 of 37.4 percent for BESREMi versus 3.6 percent for anagrelide, a more than tenfold difference in the proportion of patients achieving the trial's definition of disease control. The trial also demonstrated durable hematologic control and a reduction in thromboembolic events over 12 months, the outcomes that matter most to patients whose primary risk is blood clotting. American Pharmaceutical Review reported on Sep 1 that the FDA's approval is not restricted by genetic subtype, meaning it covers the range of mutations that drive the disease, including the JAK2, CALR and MPL mutations, as well as patients with no identifiable driver mutation.

The practical significance of the label is that it is broad. PharmaEssentia said in its August 31 announcement that BESREMi is approved for adults with essential thrombocythemia regardless of genotype or disease status, including patients who have not previously received cytoreductive therapy. That breadth matters because ET is a heterogeneous disease, and many patients, particularly those diagnosed through incidental blood tests, are younger and face decades of living with the condition, making the long-term safety profile of any therapy a central consideration. BESREMi's dosing regimen, a subcutaneous injection starting at 250 micrograms and rising to a 500 microgram maintenance dose every two weeks, is designed for chronic use, and the drug's prolonged half-life, achieved through a monopegylation technology, allows the two-week interval that distinguishes it from older interferons requiring more frequent injection.

The approval carries an interferon class boxed warning, reflecting the known risks of interferon alfa therapies, which can cause or aggravate serious neuropsychiatric, autoimmune, ischemic and infectious disorders. BioSpectrum Asia reported on Sep 2 that common adverse reactions in the trial included elevated transaminases, anemia, fever, bacterial infection, pruritus and weight loss, a safety profile that physicians will need to weigh against the thrombosis risk the drug is designed to reduce. The US approval follows regulatory clearances in Japan and Taiwan, giving PharmaEssentia a global launch sequence across three major markets and a foundation of real-world experience in the two Asian markets where the drug has been available longest.

Analysis

What this really means is that the treatment of myeloproliferative neoplasms is finally moving from symptom management toward disease modification, and essential thrombocythemia is the latest front in that shift. The old standard of care, hydroxyurea and anagrelide, works by suppressing the bone marrow's production of blood cells, but it does not selectively target the malignant clone that causes the disease, which is why patients often relapse when treatment is stopped and why the drugs must be taken indefinitely. Interferon-based therapy works differently, by modulating the immune system's response to the malignant cells and, in a meaningful subset of patients, reducing the proportion of cells carrying the disease-driving mutation. The SURPASS ET result, a 37.4 percent durable response rate against anagrelide's 3.6 percent, is the strongest evidence yet that this disease-modifying approach can produce deep, lasting responses in ET, and it validates the broader thesis that has driven the adoption of interferons in polycythemia vera.

The bigger picture here is the commercial logic for PharmaEssentia and the competitive dynamics it reveals. BESREMi was already approved for polycythemia vera, and the ET indication roughly doubles the company's addressable patient population in a disease where treatment options have been stagnant for three decades. For a company that built its franchise on a single molecule, the second indication is a milestone that diversifies its revenue base and strengthens its position with the hematologists who treat both diseases. The approval also sharpens the contrast with the emerging small-molecule treatments for these diseases, which target the specific mutations that drive them but require daily oral dosing and come with their own toxicity profiles. Interferon therapy and targeted therapy are not mutually exclusive, and the coming years are likely to see combinations explored, but the ET approval gives the interferon approach a foothold in a disease where it previously had none.

The limitations deserve attention. A 37.4 percent durable response rate means that nearly two-thirds of patients in the trial did not achieve the protocol's definition of response, and while that is far better than the 3.6 percent seen with anagrelide, it is a reminder that BESREMi is not a cure and that many patients will need additional or alternative therapy. The boxed warning for neuropsychiatric and autoimmune disorders is a real constraint, particularly for younger patients who may be reluctant to accept the risk of depression or other psychiatric side effects from a therapy they might take for decades. And the trial's design, which enrolled patients who had failed hydroxyurea, means the evidence is strongest in the refractory population, while the broad label that includes treatment-naive patients rests on a smaller evidence base. Physicians will need to exercise judgment about which patients are most likely to benefit, and the drug's uptake will depend as much on that clinical judgment as on the approval itself.

Why It Matters

For the estimated patient population with essential thrombocythemia who have run out of options on hydroxyurea or cannot tolerate anagrelide, the approval provides a mechanistically new treatment that has been shown to produce durable responses in a meaningful proportion of patients, and it comes with a dosing schedule, one injection every two weeks, that is far more convenient than the daily pills it may replace. For hematologists, the approval adds a third pillar to the ET treatment algorithm and gives them a disease-modifying option to discuss with patients who have been managing a chronic cancer with therapies that do not address the underlying disease. For PharmaEssentia, the second indication transforms the company's commercial trajectory by roughly doubling its addressable market in the United States and giving it a platform for further expansion into related myeloproliferative neoplasms. For the broader field, the approval is a signal that regulatory agencies and drug developers are willing to invest in rare blood cancers where the patient numbers are small but the unmet need is large, and it may encourage more development in a category that has been neglected for decades.

Next Up

In the coming months, watch for the launch execution, including the drug's pricing, patient access programs and the reimbursement decisions that will determine how quickly BESREMi reaches patients in the ET indication. Watch also for the real-world evidence that accumulates as the drug is used beyond the clinical trial population, particularly in treatment-naive patients and in those with different genetic subtypes, since the broad label rests on data that is strongest in the hydroxyurea-refractory group. The most important near-term signal will be the response from the medical community, both in updated treatment guidelines and in prescribing patterns, because the extent to which hematologists embrace a disease-modifying therapy with a boxed warning will determine whether this approval marks a true turning point in ET care or a modest addition to an unchanged standard of care.